| 2025-04-09 | -28.5% | news | Seeking Alpha | Lucid Diagnostics announces proposed public offering of common stock |
| 2025-04-10 | -26.4% | news | Seeking Alpha | Lucid Diagnostics stock falls after pricing capital raise of $15M via stock offering |
| 2025-04-10 | -26.4% | legal | SEC EDGAR | LUCD 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-04-10 | -26.4% | news | Stocktwits | Lucid Diagnostics Stock Sinks After-Hours On Equity Raise, But Retail Dives In Anyway - Stocktwits |
| 2021-10-15 | -21.6% | earnings | MarketBeat | Lucid Diagnostics (LUCD) Stock Price, News & Analysis - MarketBeat |
| 2021-10-15 | -21.6% | analyst | Benzinga | Lucid Diagnostics Analyst Ratings and Price Targets | NASDAQ:LUCD - Benzinga |
| 2021-10-15 | -21.6% | earnings | MarketBeat | Top Lucid Diagnostics (LUCD) Competitors 2026 - MarketBeat |
| 2021-10-15 | -21.6% | earnings | MarketBeat | Lucid Diagnostics (LUCD) Earnings Date and Reports 2026 - MarketBeat |
| 2026-04-23 | -18.7% | news | MT Newswires | Lucid Diagnostics Prices Registered Direct Offering of 18 Million Shares |
| 2026-04-23 | -18.7% | news | PR Newswire | Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock |
| 2026-04-23 | -18.7% | news | Seeking Alpha | Lucid Diagnostics announces $18M offering of common stock |
| 2026-04-23 | -18.7% | legal | SEC EDGAR | LUCD 8-K: 1.01, 7.01 (SEC Filing) |
| 2026-04-23 | -18.7% | news | TradingView | Lucid Diagnostics Prices $18 Million Underwritten Offering at $1 Per Share With Canaccord and BTIG - TradingView |
| 2026-04-23 | -18.7% | news | Stock Titan | A $15M anchor investor backs Lucid’s 18M-share stock sale - Stock Titan |
| 2026-04-23 | -18.7% | news | Stock Titan | Lucid Diagnostics (Nasdaq: LUCD) prices $18M underwritten stock sale - Stock Titan |
| 2026-04-23 | -18.7% | news | TipRanks | Lucid Diagnostics Prices $18 Million Public Equity Offering - TipRanks |
| 2026-04-23 | -18.7% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | LUCD Lucid Diagnostics shares rise 4.4 percent on Q4 2025 EPS beat and 8.3 percent year over year revenue growth. - Market Expert Watchlist - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -18.7% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Lucid Diagnostics (LUCD) Annual Recap | Lucid Diagnostics posts 2% EPS beat, beats consensus loss estimates - Dividend Cut Risk - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -18.7% | earnings | Xã Thanh Hà | LUCD Lucid Diagnostics shares rise 4.4 percent on Q4 2025 EPS beat and 8.3 percent year over year revenue growth. - Surprise Factor - Xã Thanh Hà |
| 2026-04-23 | -18.7% | earnings | Xã Thanh Hà | Lucid Diagnostics (LUCD) Annual Recap | Lucid Diagnostics posts 2% EPS beat, beats consensus loss estimates - Turnaround Phase - Xã Thanh Hà |
| 2025-05-30 | -18.5% | legal | SEC EDGAR | LUCD 8-K: 1.01 and (SEC Filing) |
| 2025-09-09 | -17.3% | news | Seeking Alpha | Lucid Diagnostics announces proposed public offering of common stock |
| 2025-09-10 | -16.9% | news | Seeking Alpha | Lucid Diagnostics dips after pricing $25M stock offering |
| 2025-09-10 | -16.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 7.01 (SEC Filing) |
| 2026-04-13 | +15.2% | news | Stock Titan | Lucid Diagnostics (LUCD) CMO holds 650K shares including restricted stock - Stock Titan |
| 2023-01-18 | -14.4% | legal | SEC EDGAR | LUCD 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-01-21 | -13.3% | expansion | Seeking Alpha | PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract |
| 2026-01-21 | -13.3% | expansion | PR Newswire | Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® - PR Newswire |
| 2026-01-21 | -13.3% | news | Stock Titan | VA taps Lucid's EsoGuard cancer test, opening access for 9M veterans - Stock Titan |
| 2026-01-21 | -13.3% | expansion | Investing.com Nigeria | Lucid Diagnostics stock surges after securing VA contract for cancer test - Investing.com Nigeria |
| 2026-01-21 | -13.3% | expansion | Seeking Alpha | PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract - Seeking Alpha |
| 2026-01-21 | -13.3% | news | TipRanks | Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today? - TipRanks |
| 2026-01-21 | -13.3% | news | Benzinga | Why Is PAVmed Stock Skyrocketing Wednesday? - Benzinga |
| 2026-01-21 | -13.3% | news | TradingView | Should you chase the rally in PAVmed stock after it quadrupled on Wednesday? - TradingView |
| 2026-01-21 | -13.3% | expansion | Investing.com | Lucid Diagnostics secures VA contract for esophageal cancer test - Investing.com |
| 2026-01-21 | -13.3% | M&A | Stocktwits | PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs? - Stocktwits |
| 2026-01-21 | -13.3% | expansion | parameter.io | Lucid Diagnostics Inc. (LUCD) stock: slides after early spike despite major VA contract win - parameter.io |
| 2025-05-23 | +12.9% | news | Intellectia AI | LUCD Forecast — Price Prediction for 2026. Should I Buy LUCD? - Intellectia AI |
| 2023-11-14 | +12.5% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-11-16 | -12.1% | news | Business Wire | PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results - Business Wire |
| 2022-11-14 | -10.3% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-11-13 | +10.2% | legal | SEC EDGAR | LUCD 8-K: 5.02 and (SEC Filing) |
| 2023-03-13 | +9.5% | legal | SEC EDGAR | LUCD 8-K: 3.02, 3.03, 5.03 (SEC Filing) |
| 2023-03-14 | +8.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 2.02, 2.03, 3.02, 3.03, 7.01 (SEC Filing) |
| 2024-05-07 | -8.8% | legal | SEC EDGAR | LUCD 8-K: 3.02, 3.03, 5.02, 5.03, 7.01 (SEC Filing) |
| 2022-05-12 | +8.5% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-09 | +8.0% | news | parameter.io | Lucid Diagnostics (LUCD) Stock: Surge After Real-World EsoGuard Data Breakthrough! - parameter.io |
| 2024-03-14 | -7.8% | legal | SEC EDGAR | LUCD 8-K: 3.02, 3.03, 5.03 (SEC Filing) |
| 2025-09-08 | -7.8% | news | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript) |
| 2025-09-08 | -7.8% | news | PR Newswire | Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 - PR Newswire |
| 2025-03-05 | +7.6% | legal | SEC EDGAR | LUCD 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-04-11 | -7.6% | legal | SEC EDGAR | LUCD 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-05-20 | +7.6% | news | Investing.com | Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com |
| 2022-03-29 | +7.3% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-08 | +7.2% | legal | Seeking Alpha | Lucid Diagnostics files for $175 mln mixed securities shelf offering |
| 2024-08-12 | +7.2% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-05-14 | -7.1% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-12-02 | +6.7% | legal | SEC EDGAR | LUCD 8-K: 3.02 and (SEC Filing) |
| 2026-02-04 | -6.3% | news | Stock Titan | PAVmed wipes out legacy convertibles in $45M balance-sheet reset - Stock Titan |
| 2022-01-13 | -6.2% | earnings | MarketBeat | Lucid Diagnostics (LUCD) Short Interest & Short Float | Updated Apr 2026 - MarketBeat |
| 2025-10-16 | -6.2% | news | Yahoo Finance | What Makes Lucid Diagnostics Inc. (LUCD) a Strong Momentum Stock: Buy Now? - Yahoo Finance |
| 2022-03-28 | +6.0% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-04-06 | +5.8% | news | CoinCodex | Lucid Diagnostics Inc. (LUCD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2022-03-23 | +5.7% | legal | SEC EDGAR | LUCD 8-K: 5.02 and (SEC Filing) |
| 2025-11-11 | +5.4% | earnings | Yahoo Finance | Lucid Diagnostics Inc (LUCD) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance |
| 2025-11-12 | +4.5% | news | Seeking Alpha | Lucid Diagnostics signals imminent Medicare coverage for EsoGuard while strengthening commercial payer engagement |
| 2025-11-12 | +4.5% | earnings | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript |
| 2025-11-12 | +4.5% | earnings | Seeking Alpha | Lucid Diagnostics Non-GAAP EPS of -$0.10 misses by $0.01, revenue of $1.21M misses by $0.14M |
| 2025-11-12 | +4.5% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-12 | +4.5% | earnings | Yahoo Finance | Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2025-03-25 | +4.3% | earnings | Seeking Alpha | Lucid Diagnostics targets revenue growth with expanded sales initiatives and Medicare coverage prospects |
| 2025-03-25 | +4.3% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-29 | -4.3% | news | Yahoo Finance | Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30% - Yahoo Finance |
| 2026-04-18 | +4.2% | earnings | MarketBeat | Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat |
| 2025-12-13 | -4.2% | news | simplywall.st | Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt? - simplywall.st |
| 2024-11-18 | -3.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 2.03, 3.02, 3.03 (SEC Filing) |
| 2022-03-03 | -3.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 2.01, 3.02, 5.02, 7.01 (SEC Filing) |
| 2022-08-15 | -3.9% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-05-24 | -3.7% | legal | SEC EDGAR | LUCD 8-K: 8.01 and (SEC Filing) |
| 2022-06-22 | +3.6% | legal | SEC EDGAR | LUCD 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-07-16 | -3.5% | news | Seeking Alpha | Lucid says meeting scheduled to determine Medicare coverage for cancer test |
| 2026-03-12 | -3.4% | executive | Stock Titan | Lucid Diagnostics CEO to detail growth strategy in March 26 call - Stock Titan |
| 2022-01-20 | +3.3% | legal | SEC EDGAR | LUCD 8-K: 5.02 and (SEC Filing) |
| 2026-04-20 | +3.3% | news | Stock Titan | Lucid Diagnostics (NASDAQ: LUCD) seeks 100M-share authorization increase - Stock Titan |
| 2026-04-20 | +3.3% | news | MSN | Needham Reiterates Lucid Diagnostics (LUCD) Buy Recommendation - MSN |
| 2026-04-20 | +3.3% | news | Cổng thông tin điện tử tỉnh Lào Cai | Lucid Diagnostics (LUCD) Stock: Why It Matters Now (+3.20%) 2026-04-20 - Community Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-08-12 | -3.1% | earnings | Yahoo Finance | What To Expect From Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings - Yahoo Finance |
| 2023-10-18 | +3.0% | legal | SEC EDGAR | LUCD 8-K: 3.02, 3.03, 5.03 (SEC Filing) |
| 2023-02-17 | +3.0% | legal | SEC EDGAR | LUCD 8-K: 1.02, 3.02 (SEC Filing) |
| 2025-02-25 | +3.0% | legal | SEC EDGAR | LUCD 8-K: 8.01 and (SEC Filing) |
| 2026-03-25 | -2.9% | earnings | Quiver Quantitative | Lucid Diagnostics Inc. (LUCD) Stock Rises on Q4 2025 Earnings - Quiver Quantitative |
| 2026-03-25 | -2.9% | earnings | TradingView | Lucid Diagnostics 2025 10-K: Revenue $4.7M, Net Loss $58.0M - TradingView |
| 2024-11-29 | -2.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 1.02, 2.03, 3.02, 3.03 (SEC Filing) |
| 2025-05-14 | +2.7% | news | Seeking Alpha | Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances |
| 2025-05-14 | +2.7% | earnings | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript |
| 2025-05-14 | +2.7% | earnings | Seeking Alpha | Lucid Diagnostics Non-GAAP EPS of -$0.16 misses by $0.06, revenue of $0.83M misses by $0.71M |
| 2025-05-14 | +2.7% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-10 | +2.7% | news | Quiver Quantitative | Lucid Diagnostics Stock (LUCD) Opinions on Recent Clinical Data Release | LUCD Stock News - Quiver Quantitative |
| 2025-12-30 | +2.7% | news | Stock Titan | 1-for-30 reverse split aims to keep PAVmed shares on Nasdaq exchange - Stock Titan |
| 2025-09-29 | -2.6% | news | Seeking Alpha | Lucid Diagnostics: Holding Onto Medicare Coverage Hopes |
| 2025-09-29 | -2.6% | news | Seeking Alpha | Lucid Diagnostics: Holding Onto Medicare Coverage Hopes (NASDAQ:LUCD) - Seeking Alpha |
| 2021-12-23 | +2.6% | earnings | MarketBeat | Lucid Diagnostics (LUCD) Institutional Ownership 2026 - MarketBeat |
| 2026-03-26 | -2.4% | earnings | GuruFocus.com | Lucid Diagnostics Inc (LUCD) Q4 2025 Earnings Call Highlights: Strong Test Volume Growth and ... |
| 2026-03-26 | -2.4% | earnings | Moby | Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary |
| 2026-03-26 | -2.4% | earnings | MarketBeat | Lucid Diagnostics Q4 Earnings Call Highlights |
| 2026-03-26 | -2.4% | news | Seeking Alpha | Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins |
| 2026-03-26 | -2.4% | earnings | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript |
| 2026-03-26 | -2.4% | earnings | Seeking Alpha | Lucid Diagnostics Non-GAAP EPS of -$0.10 misses by $0.02, revenue of $1.5M beats by $0.11M |
| 2026-03-26 | -2.4% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-26 | -2.4% | news | PR Newswire | Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire |
| 2026-03-26 | -2.4% | earnings | Yahoo Finance | Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2026-03-26 | -2.4% | legal | Stock Titan | [EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan |
| 2026-03-26 | -2.4% | news | Investing.com | Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com |
| 2026-03-26 | -2.4% | earnings | The Globe and Mail | Lucid Diagnostics (LUCD) Earnings Transcript - The Globe and Mail |
| 2025-07-28 | -2.4% | news | Seeking Alpha | Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG |
| 2022-02-13 | -2.3% | news | ChartMill | LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill |
| 2026-04-02 | -2.3% | expansion | PR Newswire | PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio |
| 2026-04-02 | -2.3% | expansion | Stock Titan | Duke-licensed esophageal imaging joins PAVmed device relaunch - Stock Titan |
| 2026-04-09 | +2.2% | news | PR Newswire | Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-09 | +2.2% | news | PR Newswire | Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - PR Newswire |
| 2026-04-09 | +2.2% | earnings | MarketBeat | Lucid Diagnostics Inc. $LUCD Shares Purchased by Aberdeen Group plc - MarketBeat |
| 2026-04-09 | +2.2% | earnings | MarketBeat | Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $9.00 - MarketBeat |
| 2026-04-09 | +2.2% | executive | Stock Titan | Lucid CEO to speak at Needham healthcare conference on April 16 - Stock Titan |
| 2025-08-13 | -2.1% | earnings | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript |
| 2025-08-13 | -2.1% | earnings | Seeking Alpha | Lucid Diagnostics Non-GAAP EPS of -$0.10 |
| 2025-08-13 | -2.1% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-13 | -2.1% | legal | PR Newswire | Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - PR Newswire |
| 2026-03-27 | +2.0% | earnings | Seeking Alpha | Lucid Diagnostics Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-27 | +2.0% | earnings | Seeking Alpha | Lucid Diagnostics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha |
| 2026-03-27 | +2.0% | analyst | The Globe and Mail | Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail |
| 2025-07-27 | -1.8% | news | Quiver Quantitative | LUCD | Lucid Diagnostics Inc. Common Institutional Ownership - Quiver Quantitative |
| 2024-11-13 | +1.6% | legal | SEC EDGAR | LUCD 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-24 | -1.3% | earnings | Yahoo Finance | Here’s Why Lucid Diagnostics (LUCD) Declined in Q3 - Yahoo Finance |
| 2022-04-01 | +1.2% | legal | SEC EDGAR | LUCD 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-09-25 | -1.1% | legal | SEC EDGAR | LUCD 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-01-30 | -1.1% | legal | SEC EDGAR | LUCD 8-K: 3.02 and (SEC Filing) |
| 2025-11-14 | +0.9% | earnings | Seeking Alpha | Lucid Diagnostics Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2024-12-20 | -0.9% | legal | SEC EDGAR | LUCD 8-K: 8.01 and (SEC Filing) |
| 2024-06-12 | +0.9% | news | Stock Titan | 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing - Stock Titan |
| 2025-03-04 | +0.9% | legal | SEC EDGAR | LUCD 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-03-04 | +0.9% | legal | SEC EDGAR | LUCD 8-K: 8.01 and (SEC Filing) |
| 2022-08-02 | +0.8% | legal | SEC EDGAR | LUCD 8-K: 5.02 and (SEC Filing) |
| 2024-05-11 | +0.6% | earnings | MarketBeat | Lucid Diagnostics (LUCD) Stock Forecast and Price Target 2026 - MarketBeat |
| 2026-03-16 | -0.6% | earnings | Stock Titan | PAVmed executives to outline 2025 strategy, Q4 results on March 30 call - Stock Titan |
| 2026-04-08 | -0.5% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Is Lucid Diagnostics (LUCD) Stock Slowing Down | Price at $1.15, Up 2.23% - Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-08 | -0.5% | news | Xã Thanh Hà | Is Lucid Diagnostics (LUCD) Stock Slowing Down | Price at $1.15, Up 2.23% - Money Flow - Xã Thanh Hà |
| 2022-10-18 | -0.5% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Lucid Diagnostics (LUCD) - Zacks Investment Research |
| 2021-10-17 | -0.3% | earnings | Zacks Investment Research | What date does Lucid Diagnostics's (LUCD) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2021-10-17 | -0.3% | analyst | Investing.com | Lucid Diagnostics (LUCD) Stock Forecast & Price Target - Investing.com |
| 2021-10-17 | -0.3% | news | Zacks Investment Research | Should I buy Lucid Diagnostics (LUCD) - Zacks Investment Research |
| 2024-11-12 | +0.3% | legal | SEC EDGAR | LUCD 8-K: 1.01, 1.02, 2.03, 3.02, 3.03 (SEC Filing) |
| 2025-04-24 | +0.3% | news | Seeking Alpha | PAVmed, Lucid post encouraging results from EsoGuard study |
| 2021-10-18 | -0.2% | legal | SEC EDGAR | LUCD 8-K: 8.01 and (SEC Filing) |
| 2022-11-01 | -0.2% | analyst | TradingView | LUCD Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-09-11 | +0.2% | legal | SEC EDGAR | LUCD 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-03-24 | -0.1% | legal | SEC EDGAR | LUCD 8-K: 1.01, 2.03, 3.02, 3.03 (SEC Filing) |
| 2026-03-30 | +0.1% | news | PR Newswire | PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-30 | +0.1% | earnings | Investing.com | BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com |
| 2026-03-30 | +0.1% | news | Stock Titan | Cancer screening test wins VA access for 9 million veterans - Stock Titan |
| 2026-01-26 | -0.1% | news | Seeking Alpha | Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral |
| 2026-01-26 | -0.1% | news | Seeking Alpha | Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral (LUCD) - Seeking Alpha |
| 2025-03-24 | -0.1% | earnings | Seeking Alpha | Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript |
| 2025-03-24 | -0.1% | earnings | Seeking Alpha | Lucid Diagnostics Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-03-24 | -0.1% | earnings | Seeking Alpha | Lucid Diagnostics Non-GAAP EPS of -$0.19 misses by $0.04, revenue of $1.19M misses by $0.23M |
| 2026-04-24 | — | news | MT Newswires | Lucid Diagnostics Completes $18 Million Direct Offering of Shares |
| 2026-04-24 | — | news | PR Newswire | Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock |
| 2026-04-24 | — | legal | SEC EDGAR | LUCD 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-04-24 | — | news | PR Newswire | Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock - PR Newswire |
| 2026-04-24 | — | news | Stock Titan | Lucid Diagnostics (NASDAQ: LUCD) closes $18M underwritten stock sale - Stock Titan |
| 2026-04-24 | — | news | ChartMill | Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock - ChartMill |
| 2026-04-24 | — | news | MSN | Lucid Diagnostics announces $18M offering of common stock - MSN |
| 2026-04-24 | — | news | TipRanks | Lucid Diagnostics Raises Capital Through Direct Share Offering - TipRanks |
| 2026-04-24 | — | news | Stock Titan | Backed by a $15M investor, Lucid closes $18M share sale - Stock Titan |
| 2026-04-24 | — | news | TradingView | Lucid Diagnostics closes $18M underwritten offering, issues 18M shares at $1.00 - TradingView |
| 2026-04-24 | — | news | Stock Titan | Lucid Diagnostics (LUCD) CMO reports 650K restricted shares and 100K options - Stock Titan |
| 2026-04-24 | — | news | Intellectia AI | Lucid Diagnostics Closes $18 Million Share Offering - Intellectia AI |
| 2021-10-14 | — | news | TradingView | LUCD Stock Price and Chart — NASDAQ:LUCD - TradingView |
| 2021-10-14 | — | news | Stock Titan | Latest LUCD News - Lucid Diagnostics Announces Closing of $18 ... - Stock Titan |
| 2021-10-14 | — | news | InvestorPlace | PAVM Stock: One Big Reason Why PAVmed Is Plunging Today - InvestorPlace |